Lipocine Inc. (NASDAQ:LPCN) moved with change of -7.91% to $1.46 with the total traded volume of 387582 shares versus to an average volume of 768.65K. The stock was down in the 5 days activity -7.06%. The one month performance of stock was high 22.48%. LPCN [NASD] shares are -55.99% for the quarter and driving a -59.49% over the course of the past year and is now -54.07% since this point in 2018. Right now ABC beta is -0.29. The average volatility for the week and month was at 8.65% and 11.13% respectively.
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today declared financial results for the fourth quarter and fiscal year ended December 31, 2017.
Full Year 2017 Financial Results
Lipocine reported a net loss of $21.0 million, or ($1.05) per diluted share, for the year ended December 31, 2017, compared with a net loss of $19.0 million, or ($1.04) per diluted share, for the year ended December 31, 2016.
Research and development expenses were $11.0 million during the year ended December 31, 2017, compared with $8.1 million during the year ended December 31, 2016. The increase in research and development expenses was primarily due to increased contract research organization and consultant costs TLANDO related to the Dosing Validation (“DV”) and Dosing Flexibility (“DF”) clinical studies, increased contract manufacturing costs for LPCN 1107 and increased outside services expenses related to the Advisory Committee meeting for TLANDO. These increases were offset by decreased contract research organization costs for LPCN 1111, a decrease in validation and commercial batch manufacturing costs for TLANDO, and a decrease in contract research organization costs for LPCN 1107.
General and administrative expenses were $10.2 million during the year ended December 31, 2017, compared with $10.4 million during the year ended December 31, 2016. The decrease in general and administrative expenses during the year ended December 31, 2017 was primarily due to decreases in pre-commercialization marketing and sales activities related to TLANDO offset by an increase related to the class-action litigation settlement liability.
As of December 31, 2017, Lipocine had cash, cash equivalents, and marketable securities of $21.5 million, compared to cash, cash equivalents, and marketable securities of $26.8 million at December 31, 2016.
Shares of Lipocine Inc. have been recently spotted trading -72.70% off of the 52-week high price. On the other end, company shares have been noted 26.52% away from the low price over the last 52-weeks. 52 week range of the stock remained $ 1.15 – 5.33. Switching over to some distances from popular moving averages, we see that the stock has been recorded -19.95% away from the 50 day moving average and -57.37% away from the 200 day moving average. Moving closer, we can see that shares have been trading 1.29% off of the 20-day moving average.